Zhejiang Gaozhi Pharmaceutical Technology

Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. (Gaozhi Pharma) is a China-based pharmaceutical company headquartered in Hangzhou, specializing in the development and commercialization of high-end generic drugs and innovative small molecule therapeutics. Founded in 2021, the company has rapidly expanded its portfolio, securing over 55 drug registration certificates, including approvals for Clopidogrel bisulfate, Progesterone soft capsules, and Iguratimod tablets. Gaozhi Pharma operates as a technology-driven group that integrates R&D, manufacturing, and sales, with a strong focus on therapeutic areas such as cardiovascular health, endocrinology, and rheumatology. In addition to its robust generic pipeline, the company is advancing two innovative drug candidates in the pre-clinical stage. Recognized as a national high-tech enterprise and a "quasi-unicorn," Gaozhi Pharma continues to invest heavily in R&D to provide high-quality, affordable medicine to patients. The company maintains strategic partnerships with leading CROs and CDMOs to accelerate its drug development programs.